Skip to main content
OpenTrials
Completed

NCT Number: NCT02810938

MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology

* Prospective Atrial Flutter Ablation Registry investigating IntellaTip Mifi XP 8 mm technology and MVG isthmus ablation approach * Design: National, multi-centre, prospective observational registry documenting right atrial isthmus ablation * Observational treatment: Combination of MVG ablation strategy and the IntellaTip Mifi XP 8 mm sensor technology * Duration: Patients will be followed for 6 months post-ablation

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The MIFI Flutter Registry is a non-interventional, multi-centre, prospective registry in consecutive patients with atrial flutter and indication for right atrial isthmus ablation. The registry is an observational study and patient's participation in this study has no impact on his/her indication for treatment, diagnostics or therapy. Patients are supposed to be treated according to current guidelines and the site's internal directives.

Treatment pattern and treatment initiation, continuation or changes are solely at the discre-tion of the physician and the patient. There will be no attempt to influence the treatment patterns of any individual treating physician. All drug prescriptions will be in the usual standard of care. Participation in the registry will in no way influence payment or reimbursement for any treatment received by subjects during the study.

A minimum of 10 hospitals in Germany treating atrial flutter and using the Maximum voltage-guided (MVG) ablation technique are eligible for participation. The enrolment period is estimated to be 6 months.

Eligible are all patients with atrial flutter, who will visit consecutively a participating site of the MIFI Flutter Registry. It is planned to enrol approximately 120 patients in total.

The follow-ups of patients will be performed using a standardized patient interview (telephone call) at 6 months by Institut für Herzinfarktforschung (IHF). In case of relevant complications, the treating physician is asked to provide medical records for verification. If the patient is not accessible by phone, local registration offices will be contacted for further information.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Atrial flutter and clinical indication for atrial flutter (AFL) ablation
  • 18+ years
  • Written informed consent for participation in observational study (incl. telephone follow-ups)
  • Not simultaneously participating in any randomized trial
  • At least one ECG-documented, symptomatic, typical atrial flut-ter episode >30sec.
  • Isthmus ablation conducted in association with other ablation procedures (e.g. for atrial fibrillation) is permitted

Exclusion criteria

  • Any prior AFL ablation
  • Acute reversible causes for atrial flutter (e.g. acute myocarditis)
  • Tricuspid valve replacement
  • Right atrial thrombus
  • Present pregnancy or breastfeeding woman
  • Drug or alcohol abuse

Treatment and study plan

Ablation of atrial flutter

Device

Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach

Other names: Isthmus ablation

Primary outcomes

  1. Cumulative time [seconds] of radiofrequency catheter ablation and energy [Joule] delivery to achieve bidirectional isthmus block

    Time frame: 1 day

    evaluate radiofrequency catheter ablation of atrial flutter, i.e. the combination of MVG ablation strategy and the IntellaTip Mifi XP 8 mm sensor technology in right atrial ablation in patients with atrial flutterbidirectional isthmus block

Secondary outcomes

  1. Safety

    Time frame: 6 months

    Number of patients with cardiovascular and cerebrovascular events

  2. Effectiveness

    Time frame: 6 months

    Number of patients with recurrence of atrial flutter and/or re-ablation of atrial flutter

Sponsors and collaborators

Lead sponsor

Stiftung Institut fuer Herzinfarktforschung

Other

Collaborators

  • Boston Scientific Corporation

Registry information

Official study title

Prospective Atrial Flutter Ablation Registry Investigating IntellaTip Mifi XP 8 mm Technology and Maximum Voltage-guided (MVG) Isthmus Ablation Approach

Acronym: MIFI

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Jun 23, 2016
Registry last updated
Oct 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.